January 13, 2020

BSE Limited,
Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

The National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

Re: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Subject: U.S. FDA classifies the inspection of Lupin's Tarapur facility as OAI

The Company has received a communication from the U.S. FDA classifying the inspection conducted at its Tarapur manufacturing (API) facility between September 16 to September 20, 2019 as Official Action Indicated (OAI).

The inspection at the Tarapur facility had closed with three observations. The Company does not believe that this inspection classification will have an impact on disruption of supplies or the existing revenues from operations of this facility.

The Company is in the process of sending further updates of its corrective actions to the U.S. FDA and is hopeful of a positive outcome.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For **LUPIN LIMITED**

A Pgadre

For **R. V. SATAM**
COMPANY SECRETARY
(ACS -11973)

LUPIN LIMITED MUMBAI INDIA